Tag Archives: Small player

Fate Tx, Adicet Bio, and Allogene Report Clinical Updates from Allogeneic Cell Therapies; ASH 2022 Analysis 1

ASH 2022 Analysis 1: Fate Tx, Adicet Bio, and Allogene presented clinical updates from their allogeneic cell therapies in hematological malignancies. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Positive Interim Analysis from Obe-cel’s Pivotal Ph2 FELIX Trial for r/r ALL; BLA Submission Still Anticipated by YE 2023; Autolus Receives $70M in Milestone Payments

On Thursday, December 8, 2022, Autolus announced that obe-cel’s (autologous CD19 CAR-T) Ph1/2 FELIX trial in r/r ALL has met its primary endpoint (press release). Moreover, management highlighted that they will receive $70M from Blackstone in milestone payments (press release). Below, Celltelligence provides insights on how obe-cel’s best-in-class profile could compete with Tecartus (Gilead / Kite’s CD19 CAR-T), while discussing obe-cel’s potential FDA regulatory timelines.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene’s R&D Showcase 2022: Celltelligence Analysis – Part 2

On Tuesday, November 29, Allogene held an R&D showcase (press release / presentation) featuring the advances in its hematology and solid tumor programs. Below, Celltelligence provides part 2 of its analysis on Allogene’s pipeline covering its expanded solid tumor franchise and initial clinical data from ALLO-316’s (allogeneic CD70 CAR-T) while comparing Allogene’s Dagger platform to other approaches for reducing immune rejection.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene’s R&D Showcase 2022: Celltelligence Analysis – Part 1

On Tuesday, November 29, Allogene held an R&D showcase (press release / presentation) providing updated clinical milestones and results from ALLO-501A (allogeneic CD19 CAR-T) and ALLO-715 (allogeneic BCMA CAR-T). Below, Celltelligence provides insights on the new data presented by Allogene from its hematology franchise, while discussing potential regulatory timelines for ALLO-501A and how it could compete with approved autologous CAR-Ts.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.